The panel, which consisted of 29 clinicians and the faculty of the North American Neuromodulation Society, also recommended ziconotide as the preferred option for spinal administration compared to opioids when there is a concern for recurrent granuloma, a type of inflammation that occurs when immune cells collect. The expert panel recommendation was based on an extensive literature search and a survey of more than 15,000 clinicians worldwide.
Sign up for our FREE Pain E-Weekly for more coverage like this sent to your inbox!
Related Articles on Pain Management:
What Can Legislators Do Right Now to Positively Impact Pain Management? 5 Physician Responses
ASC Specialty to Watch: Pain Management in 2012
15 Statistics on Pain Management Case Revenue
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
